American International Group Inc. Sells 188 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

American International Group Inc. trimmed its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 0.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 46,627 shares of the company’s stock after selling 188 shares during the quarter. American International Group Inc.’s holdings in Vaxcyte were worth $2,928,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Eventide Asset Management LLC lifted its position in shares of Vaxcyte by 54.5% during the 4th quarter. Eventide Asset Management LLC now owns 607,206 shares of the company’s stock worth $38,133,000 after buying an additional 214,206 shares during the last quarter. Parkman Healthcare Partners LLC lifted its position in shares of Vaxcyte by 12.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 267,594 shares of the company’s stock worth $16,805,000 after buying an additional 29,462 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Vaxcyte during the 4th quarter worth $32,970,000. Capital Research Global Investors lifted its position in shares of Vaxcyte by 2.3% during the 4th quarter. Capital Research Global Investors now owns 3,440,107 shares of the company’s stock worth $216,039,000 after buying an additional 75,980 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC lifted its position in shares of Vaxcyte by 3.3% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 27,219 shares of the company’s stock worth $1,709,000 after buying an additional 877 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $61.27, for a total value of $490,160.00. Following the completion of the sale, the chief financial officer now owns 95,679 shares of the company’s stock, valued at $5,862,252.33. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, SVP Mikhail Eydelman sold 1,667 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $72.06, for a total transaction of $120,124.02. Following the completion of the sale, the senior vice president now owns 31,161 shares of the company’s stock, valued at $2,245,461.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total value of $490,160.00. Following the sale, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at approximately $5,862,252.33. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,483 shares of company stock valued at $4,913,533. Company insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $95.00 price objective on shares of Vaxcyte in a research report on Thursday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th.

Vaxcyte Trading Up 1.1 %

Vaxcyte stock opened at $75.78 on Tuesday. The company has a market capitalization of $8.24 billion, a PE ratio of -17.71 and a beta of 0.97. Vaxcyte, Inc. has a 12 month low of $44.20 and a 12 month high of $82.04. The stock has a 50-day moving average price of $68.44 and a two-hundred day moving average price of $67.49.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.28. As a group, analysts predict that Vaxcyte, Inc. will post -3.96 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.